Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Olanzapine: a basic science update.

F Bymaster1, K W Perry, D L Nelson

  • 1Neuroscience Research Division, Eli Lilly and Company, Indianapolis, IN, USA.

The British Journal of Psychiatry. Supplement
|April 22, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of a new schistosomicidal agent 2-[(methylpropyl)amino]-1-octanethiosulfuric acid against an oxamniquine resistant Schistosoma mansoni isolate.

Memorias do Instituto Oswaldo Cruz·1999
Same author

Regulation and function of WASp in platelets by the collagen receptor, glycoprotein VI.

Blood·1999
Same author

Retrovirus-mediated WASP gene transfer corrects defective actin polymerization in B cell lines from Wiskott-Aldrich syndrome patients carrying 'null' mutations.

Gene therapy·1999
Same author

Alternative splicing in the murine and human FXR1 genes.

Genomics·1999
Same author

The thrombocytopenia of Wiskott Aldrich syndrome is not related to a defect in proplatelet formation.

Blood·1999
Same author

Cue set size effects: sampling activated associates or cross-target interference?

Memory & cognition·1999
Same journal

Economic evaluation of the anti-stigma social marketing campaign in England 2009-2011.

The British journal of psychiatry. Supplement·2013
Same journal

Anti-stigma training for medical students: the Education Not Discrimination project.

The British journal of psychiatry. Supplement·2013
Same journal

Influence of Time to Change's social marketing interventions on stigma in England 2009-2011.

The British journal of psychiatry. Supplement·2013
Same journal

Mental health problems in the workplace: changes in employers' knowledge, attitudes and practices in England 2006-2010.

The British journal of psychiatry. Supplement·2013
Same journal

Newspaper coverage of mental illness in England 2008-2011.

The British journal of psychiatry. Supplement·2013
Same journal

Experiences of discrimination among people using mental health services in England 2008-2011.

The British journal of psychiatry. Supplement·2013
See all related articles

Olanzapine, an atypical antipsychotic, effectively treats schizophrenia symptoms by interacting with dopamine and serotonin receptors. Its unique binding profile suggests a lower risk of extrapyramidal side-effects (EPS) when dosed appropriately.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Olanzapine is an atypical antipsychotic used for schizophrenia.
  • Its broad receptor binding profile is thought to underlie its therapeutic effects.
  • Understanding its specific receptor interactions is crucial for predicting efficacy and side effects.

Purpose of the Study:

  • To investigate the in vitro and in vivo receptor binding profile of olanzapine.
  • To correlate receptor binding with neurochemical and gene expression changes in the brain.
  • To assess the potential for olanzapine to cause extrapyramidal side-effects (EPS).

Main Methods:

  • In vitro receptor binding assays to determine affinity for various neurotransmitter receptors.
  • In vivo studies assessing receptor occupancy and effects on dopaminergic pathways.

Related Experiment Videos

  • Microdialysis to measure extracellular neurotransmitter levels in specific brain regions.
  • Gene expression analysis (Fos expression) to evaluate neuronal activity.

    • Main Results:

    • Olanzapine exhibits high affinity for dopamine D2, D3, D4, 5-HT2 subtypes, 5-HT6, M1, and alpha 1-adrenergic receptors.
    • In vivo studies show potent activity at D2 and 5-HT2A receptors, with minimal activity at D1 and muscarinic receptors.
    • Olanzapine inhibits dopaminergic neurons in the A10 tract but not A9, suggesting reduced EPS risk.
    • Increased extracellular norepinephrine and dopamine in the prefrontal cortex; increased dopamine in the neostriatum and nucleus accumbens.
    • Upregulation of Fos expression in the prefrontal cortex, dorsolateral striatum, and nucleus accumbens.

    Conclusions:

    • Olanzapine's broad receptor binding profile supports its efficacy in treating both positive and negative symptoms of schizophrenia.
    • The drug's specific interaction with dopaminergic pathways suggests a favorable side effect profile regarding EPS.
    • Careful dosing of olanzapine may further mitigate the risk of adverse neurological effects.